AllDocs -> cancers

EXPRESSION PROFILING IDENTIFIES microRNA SIGNATURE IN PANCREATIC CANCER Eun Joo Lee 1 , Yuriy Gusev 2 , Jinmai Jiang 1 , Gerard J. Nuovo 4 , Megan R. Lerner 2,3 Wendy L. Frankel 4 , Daniel L. Morgan 2 , Russell G. Postier 2 , Daniel J. Brackett 2,3 and Thomas D. Schmittgen 1 1 College of Pharmacy, Ohio State University, Columbus, Ohio; 2 Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; 3 Veterans Affairs Medical Center, Oklahoma City, Oklahoma; 4 Department of Pathology, Ohio State University Medical Center, Columbus, Ohio. microRNAs are functional, 22 nt, noncoding RNAs that negatively ...

To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/458768 Combination Chemotherapy, Hyperthermia Helpful in Pancreatic , Neuroendocrine Cancer Laurie Barclay, MD Medscape Medical News 2003. © 2003 Medscape July 17, 2003 — The combination of cisplatin (CIS), gemcitabine (GEM), interferon-alpha (IFN-alpha), granulocyte-macrophage colony-stimulating factor (GM- CSF), and fever-range, long-duration whole-body hyperthermia (FR-WBH) is safe, well tolerated, and offers clinical benefit to patients with pancreatic cancer or neuroendocrine neoplasia, according to a presentation on July 14 at the 94th annual meeting of the American Association for Cancer Research (AACR) held in Washington, D.C. "The exciting implication of our phase I study is that FR-WBH increases the clinical effectiveness of optimally combined CIS, GEM and ...

Pancreatic cancer remains a cancer with poor survival prospects. For males there has been no change in incidence or mortality over the last 20 years, and for females there has been only a slight increase in both measures. Background notes Pancreatic Cancer Page 2 Male Pancreatic Cancer - Incidence and Mortality* 1977-2000 All Ages Source - SA Cancer Registry Data 0 2 4 6 8 10 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Year *Age Standardised for World Population R a t e / 1 0 0 0 0 0 Incidence Mortality Male Pancreatic Cancer Incidence and Mortality* 1977-2000 All Ages Source: SA Cancer Registry ...

Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomics Approach Mads Grønborg 1,2 , Troels Zakarias Kristiansen 1,2 , Akiko Iwahori 1 , Rubens Chang 3 , Raghunath Reddy 1 , Norihiro Sato 3 , Henrik Molina 1,2 , Ole Nørregaard Jensen 2 , Ralph H. Hruban 3,4 , Michael G. Goggins 3 , Anirban Maitra 1,3,4 and Akhilesh Pandey 1,4* 1 McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD 21205, USA 2 Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, Odense M, Denmark Department of 3 ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 April 14; 12(14): 2229-2234 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2006 The WJG Press. All rights reserved. CLINICAL RESEARCH Establishment of risk model for pancreatic cancer in Chinese Han population Xing-Hua Lu, Li Wang, Hui Li, Jia-Ming Qian, Rui-Xue Deng, Lu Zhou www.wjgnet.com Xing-Hua Lu, Jia-Ming Qian, Rui-Xue Deng, Lu Zhou. Department of Gastroenterology, Peking Union Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China Li Wang, Hui Li. Department of Epidemiology, School of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100005, China Supported by C linical Subject Fund of the Ministry of Public Health of China, No. 20010102 ...

168 www.SupportiveOncology.net T HE J OURNAL OF S UPPORTIVE O NCOLOGY L E T T E R S T O T H E E D I T O R PilotStudyofNitricOxide-DonatingAspirin inPatientsWithPancreaticCancerPain A dequatepaincontrolinpatientswith pancreatic cancer improves qual- ity of life (QOL) and may increase survival. 1 Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line medications in pancreatic cancer pain control, intend- ed to keep patients comfortable without resorting to opioids. We explored the an- algesic potential of the novel nitric oxide- donatingaspirin(NO-ASA),whichmight be much safer than ASA. 2 This single-center pilot study was con- ducted at the University Hospital, Patras Medical School, in Rion, Greece. Patients had inoperable pancreatic ...

Pancreatic Cancer Awareness Foundation Sarasota Walk – November 18, 2006 WALK SPONSOR FORM Collected By: Name _ Address _Telephone __ • To register your sponsored walk, email register@sarasotawalk.org • Please print the form and complete it in ink. • Please make checks payable to Pancreatic Cancer Awareness Foundation or PCAF , PO Box 2111, Sarasota, FL 34230. Thank you for all your help and enthusiasm. Please submit your forms and checks no later than Monday, November 9 th TOTAL COLLECTED $ ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 March 14; 12(10): 1569-1576 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2006 The WJG Press. All rights reserved. BASIC RESEARCH Cis-hydroxyproline-induced inhibition of pancreatic cancer cell growth is mediated by endoplasmic reticulum stress Christoph Mueller, Joerg Emmrich, Robert Jaster, Dagmar Braun, Stefan Liebe, Gisela Sparmann www.wjgnet.com Christoph Mueller, Joerg Emmrich, Robert Jaster, Stefan Liebe, Gisela Sparmann, Department of Medicine, Division of Gastroenterology, University of Rostock, Germany Dagmar Braun, Riemser Arzneimittel AG, Greifswald, Germany Supported by the Bundeministerium für Bildung und Forschung, grant 01ZZ0108 Correspondence to: Gisela Sparmann, MD, Department of Med- icine, Division of Gastroenterology, University ...

Allele-specific expression in familial pancreatic cancer Jian-Bing Fan 1 , Anirban Maitra 2 , Marina Bibikova 1 , Eugene Chudin 1 , Eliza Wickham Garcia 1 , David Barker 1 , Peter Chen 2 , Collins Karikari 2 , Michael G. Goggins 2 , Ralph H. Hruban 2 , and Aravinda Chakravarti 2 . 1 Illumina, Inc, San Diego, CA; 2 Johns Hopkins University, Baltimore, MD. Pancreatic cancer afflicts over 30,000 individuals each year in the United States, and is mostly lethal within months of diagnosis. About 10% of pancreatic cancer is familial due to an inherited predisposition. Despite considerable effort, germline mutations have been identified in less than 20% of families, in a few genes such ...

Review Molecular prognostic markers in pancreatic cancer : A systematic review G. Garcea a, * , C.P. Neal a , C.J. Pattenden b , W.P. Steward a , D.P. Berry b a Cancer Studies and Molecular Medicine, The Robert Kilpatrick Clinical Sciences Building, University of Leicester, The Leicester Royal Infirmary, Leicester LE2 7LX, UK b Department of Hepatobiliary and Pancreatic Surgery, The Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK Received 7 April 2005; accepted 8 April 2005 Available online 16 September 2005 Abstract Pancreatic cancer is one of the most lethal tumours of the gastrointestinal tract. The ability to predict which patients would ben- efit most from surgical intervention and/or chemotherapy would be a great clinical asset. Considerable research has focused ...

66 Brasi nien B, et al. 67 Effect of different treatment methods on survival in patients with pancreatic cancer Roczniki Akademii Medycznej w Bialymstoku · Vol. 48, 2003 · Annales Academiae Medicae Bialostocensis ADDRESS FOR CORRESPONDENCE: Birute Brasi nien Eiveniu 2, Department of Oncology, Kaunas Medical University Hospital Kaunas, Lithuania. e-mail: birutebras@yahoo.com fax: +3707 327125 Received 23.07.2003 Accepted 19.08.2003 Abstract Purpose: To assess the benefit of treatment modalities on the survival in patients with pancreatic cancer . Material and methods: Eighty-five patients with pancreatic cancer were treated by surgery, radiotherapy, chemotherapy and combined therapy. The data was reviewed retrospectively and the benefit of various treat- ment methods to the median survival time of the patients ...

JOP. J Pancreas (Online) 2006; 7(2):157-162. JOP. Journal of the Pancreas - http://www.joplink.net - Vol. 7, No. 2 - March 2006. [ISSN 1590-8577] 157 EDITORIAL Anorexia-Cachexia Syndrome in Pancreatic Cancer : Recent Development in Research and Management Generoso Uomo, Fernando Gallucci, Pier Giorgio Rabitti Department of Internal Medicine, Cardarelli Hospital. Naples, Italy Despite more than 30 years of clinical trials, the cure rate for pancreatic cancer remains less than 5% and the yearly incidence rate of this tumor virtually overlaps the mortality rate [1]. Only a small portion of patients presents potentially resectable disease but even for the patients undergoing a “curative” pancreaticoduodenectomy, the five-year survival rate remains very poor. Close to 100% of patients with pancreatic cancer develop metastases and die from ...

Prevention of Pancreatic Cancer C HAPTER 71 By Brenda J. Morrison Page 2 Prevention of Pancreatic Cancer 71 Adapted by Brenda J. Morrison, PhD 1 from the report prepared for the U.S. Preventive Services Task Force 2 N o tests have yet been developed which are suitable for screening for pancreatic cancer in asymptomatic persons. However, counselling for smoking cessation is recommended since there is fair evidence that cessation does reduce the risk of the disease and good evidence that counselling is effective. Burden of Suffering Cancer of the pancreas is the fourth leading cause of cancer deaths in Canada in both men and women, accounting for 2,611 deaths in 1990 and an estimated 36,000 potential years ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 February 7; 12(5): 765-767 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2006 The WJG Press. All rights reserved. RAPID COMMUNICATION Surgical treatment of patients with intermediate-terminal pancreatic cancer Yu-Bin Liu, Liang Huang, Zhi-Yong Xian, Zhi-Xiang Jian, Jin-Rui Ou, Zi-Xian Liu www.wjgnet.com Yu-Bin Liu, Liang Huang, Zhi-Yong Xian, Zhi-Xiang Jian, Jin-Rui Ou, Zi-Xian Liu, Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital, Guangzhou 510080, Guangdong Province, China Supported by the Medical Science Technology Foundation of Guangdong Province, No. WSTJJ20021025210102701008182 Correspondence to: Dr Yu-Bin Liu, Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital, Guangzhou 510080, Guangdong ...

ORIGINAL PAPER Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes Robert Grützmann 1,6 Hinnerk Boriss 2,6 , Ole Ammerpohl 3 , Jutta Lüttges 4 , Holger Kalthoff 3 , Hans Konrad Schackert 5 , Günter Klöppel 4 , Hans Detlev Saeger 1 and Christian Pilarsky* ,1 1 Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; 2 Interdisciplinary Center for Bioinformatics, Leipzig, Germany; 3 Department of Molecular Oncology, Clinic for General Surgery and Thoracic Surgery, University of Kiel, Germany; 4 Department of Pathology, University of Kiel, Germany; ...

B.C. Cancer Agency Protocol Summary GIPAJFF Page 1 of 4 BCCA Protocol Summary for Adjuvant Therapy for Resected Pancreatic Cancer using Leucovorin and Fluorouracil Protocol Code GIPAJFF Tumour Group Gastrointestinal Contact Physician GI Systemic Therapy ELIGIBILITY : Completely resected Stage I, II or III adenocarcinoma of the pancreas TESTS : Baseline: CBC & diff, CEA, bilirubin, calculated creatinine clearance Before each treatment: CBC & diff If clinically indicated: bilirubin PREMEDICATIONS : Treatment is non-emetogenic. See SCNAUSEA protocol. TREATMENT : See dose modifications for patients with significant co-morbid conditions. Drug Dose BCCA Administration Guideline Leucovorin (Folinic Acid) 20 mg/m 2 /day x 5 days (d1-5) IV push prior to Fluorouracil ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 January 14; 12(2):246-250 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2006 The WJG Press. All rights reserved. BASIC RESEARCH Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer Michael Hocke, Ewald Schulze, Peter Gottschalk, Theodor Topalidis, Christoph F Dietrich www.wjgnet.com Michael Hocke, Peter Gottschalk, Department of Internal Medicine II, Friedrich Schiller University Jena, Erlanger Allee 101, 07740 Jena, Germany Ewald Schulze, Department of Pathology, Friedrich Schiller Uni- versity Jena, Erlanger Allee 101, 07740 Jena, Germany Theodor Topalidis, Cytologic Institute, Doehrbruch 62, 30559 Hannover, Germany Christoph F Dietrich, Caritas Hospital, Department of Internal Medicine II, Uhlandstraße ...

ABSTRACT Pancreatic cancer still represents a serious medical concern for which no adequate solution has thus far been found. Surgery is the only appropriate therapy, but has a survival rate of around 30- 35% at three years, with an operative mortality below 3% and an operative morbidity approaching 10% of radically resected pa- tients, all of which applies to surgery performed by expert teams in highly experienced sites. Key words: Pancreatic cancer . Management. Hidalgo Pascual M, Ferrero Herrero E, Peláez Torres P, Castil- lo Fé MJ, Bonachia Naranjo O, Labalde Martínez M, Botella Ballesteros F. Pancratic cancer . Management. Rev Esp Enferm Dig 2004; 96: 784-795. INTRODUCTION Potential measures against pancreatic cancer are theo- retically many; however, these are matter-of-factly re- stricted to surgery solely, since other therapeutic proce- dures ...

THE CANCER RESEARCH SOCIETY REQUESTS GRANT APPLICATIONS ON PANCREATIC CANCER The Cancer Research Society (CRS) is proud and honoured to invite grant applications for the first CRS/Rob Lutterman Pancreatic Cancer Research Grant. The funding for this grant has been raised through the Rob Lutterman Memorial Fund. The fund was created in memory of Rob Lutterman, who passed away in 1999 of pancreatic cancer at the age of sixty-three. Family, friends, and valued members of the community created a fund to honour his memory. He was a generous man who contributed greatly to the community. This fund is a tribute to his expansive spirit. The majority of funds are raised through the annual Rob Lutterman Ski for a Cure Day, though the fund is open year round. The goal of this grant is to provide targeted funding for applications to conduct basic research on the causes of or treatments for pancreatic ...

Pancreatic Cancer : Diagnosis and Management ROBERT FREELOVE, M.D., Smoky Hill Family Medicine Residency Program, Salina, Kansas ANNE D. WALLING, M.B., Ch.B., University of Kansas School of Medicine-Wichita, Wichita, Kansas T he American Cancer Society esti- mated that 31,860 Americans would be diagnosed with pan- creatic cancer in 2004, and that 31,270 would die from the disease. 1 Pancre- atic cancer accounts for only 2 percent of all new cancers in the United States, but it is the fourth leading cause of cancer deaths. At the time of diagnosis, more than one half of pan- creatic cancers have metastasized, and only 8 percent are localized. The overall five-year survival rate is 4 percent. Localized cancers have a 17 percent survival rate. Survival rates have not improved during the past 25 years. 1 Pancreatic ...

Page 2 Pancreatic cancer in England 1998/9 to 2002/3. A geographical profile of hospital admissions. Authors: Michael Goldacre, David Yeates, Leicester Gill, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of hospital admission for cancer of the pancreas in England. The geographical areas covered are the standard local authority areas of England. The period covered is April 1 1998 to March 31 2003. The data are from Hospital Episode Statistics (HES). HES includes data on all NHS hospital admissions (including admissions for day case care). This analysis includes HES data about men and women of all ages. The maps show: (a) The spell-based admission rates per 100,000 resident population for each local ...

Shailesh Vinayak Shrikhande Dr. med. PANCREATIC CANCER AND CHRONIC PANCREATITIS: RECENT ADVANCES IN PATHOGENESIS, MOLECULAR BIOLOGY AND SURGERY Born in Pune, India, on January 18 th , 1971 Master of Surgery, University of Bombay, India September 1997 Promotionsfach: General Surgery Doctorvater: Professor Helmut Friess Molecular changes in Chronic Pancreatitis and Pancreatic Cancer To summarize, the pathogenesis of pain, tissue destruction, inflammation and fibrosis in CP is better understood today than ever before. Recent advances in cellular molecular biology have revealed complex interactions between inflammatory cells and pancreatic parenchyma cells as well as alterations in nerves. It is now clear that nerve changes, well studied and observed in alcoholic CP for over a decade, are also similar in other forms of CP such as tropical and ...

Dartmouth Medicine 13 Winter 2005 the chemotherapy was delivered in higher doses over a shorter, three-week period. This se- quence actually shrinks the pan- creatic tumor and appears to de- stroy the bits of disease that have metastasized. The surgical mem- bers of the team then found that it was easier to completely re- move the pancreatic tumor. “We’re optimistic that this technique may be successful,” says Pipas. The outlook for a pancreatic cancer patient is, he says, “still pretty bleak, but we can make more people respond to surgical resectioning.” Wilson Jones ended up as one of the 24 patients after he went to his family doctor in New Lon- don, N.H., complaining of stom- ach pain. When a CT scan re- vealed a pancreatic tumor, Jones was transferred to DHMC, where he was treated with radia- tion and high doses of the ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(48):7671-7675 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER • RAPID COMMUNICATION • CONCLUSION: The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer . The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery. © 2005 The WJG Press and Elsevier Inc. All rights reserved. Key words: Tumor antigen SC6; Pancreatic neoplasm; Immunoradiometric assay Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN. New tumor-associated antigen SC6 in pancreatic cancer . World J Gastroenterol 2005; 11(48): 7671-7675 http://www.wjgnet.com/1007-9327/11/7671.asp INTRODUCTION ...

PROGNOSTIC TUMOUR MARKERS IN PANCREATIC CANCER Anne Juuti Academic Dissertation To be presented for public examination with the permission of the Medical Faculty of the University of Helsinki, in the Auditorium 2, Meilahti Hospital, Haartmaninkatu 4, on February 3rd, 2006, at 12 noon. Department of Surgery, University of Helsinki Helsinki, Finland Page 2 Supervised by: Docent Caj Haglund M.D., PhD Department of Surgery University of Helsinki Reviewed by: Professor Timo Paavonen M.D., PhD Department of Pathology University of Oulu Docent Ilmo Kellokumpu M.D., PhD Department of Surgery Jyväskylä Central Hospital Opponent: Professor Matti Eskelinen M.D., PhD Department of Surgery University of Kuopio ISBN 952-91-9894-9 (paperback) ISBN 952-10-2935-8 (PDF) Yliopistopaino Helsinki 2006 ...

ATTACKING PANCREATIC CANCER TRANSPLANTING HOPE IN YOUNG PATIENTS STARVING TUMORS S p r i n g / S u m m e r 2 0 0 5 Sapna Syngal, MD, MPH, and Michael Carlin discuss his family’s risk for pancreatic and other cancers. Research and Care at Dana-Farber Cancer Institute Including the 2004 Annual Report Page 2 5 Making cancer cells die a ‘good death’ I t is not a distinction to be envied, but cancer this year became the number one cause of death for Americans under the age of 85, surpassing heart disease, which today claims half as many lives as it did in the 1930s. Though the statistics are staggering – nearly 1.4 million cancer diagnoses a year in this country, and nearly 600,000 deaths – cancer ’s “ascendance” to the top of the mortality charts doesn’t reflect ...

Patient Information Sheet Page 1 of 4 Version 2 - November 2001 (WPH - 19.4.02) __ GEM-CAP Trial of Chemotherapy in Advanced Pancreatic Cancer PATIENT INFORMATION SHEET You have been invited to take part in a research study. Before you decide it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if you would like more information. ‘Consumers for Ethics in Research’ (CERES) publish a leaflet called ‘Medical Research and You’. This leaflet gives more information about medical research and looks at some questions you may want to ask. A copy can be obtained from the doctor/nurse inviting you to take part or from CERES, PO Box 1365, London N16 0BW. What is the purpose of the study? ...

Patient Information Sheet Page 1 of 2 Version 3 - December 1999 (WPH - 20.7.01) Cancer Research Centre Weston Park Hospital Whitham Road Sheffield S10 2SJ U.K. ESPAC-3 –Additional Treatment in Operable Pancreatic Cancer PATIENT INFORMATION (Please read carefully) You have been invited to take part in a research study. Before you decide whether to participate it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part. This study has been designed to find out whether giving additional treatment after operation can help patients with your condition. What is the purpose of the ...

GENE MODIFIED CELL LINES AS VACCINE FOR PANCREATIC CANCER : THE JOHNS HOPKINS EXPERIENCE Dan Laheru, Barbara Biedrzycki, Ross Abrams, John Cameron, Kristen Hege, Ralph Hruban, Keith Lillemoe, Beth Onners, Sara Solt, Irena Tartakovsky, Charles Yeo, Elizabeth Jaffee The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD New therapies are urgently needed for all stages of pancreatic adenocarcinoma. We have developed a novel gene-modified whole cell allogeneic vaccine strategy for activating antitumor immune responses. Pre-clinical models have demonstrated that tumor cells genetically modified to secrete the cytokine granulocyte/macrophage-colony stimulating factor (GM-CSF) can generate potent, T cell- dependent, systemic antitumor immunity. We tested in our initial phase I trial two allogeneic GM-CSF secreting pancreatic vaccine cell lines integrated with chemoradiotherapy in 14 patients ...